Zaltrap Solution For Injection 25Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

ZALTRAP: Solution for injection (25mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

ZIV-AFLIBERCEPT (ziv a FLIB er sept) is a chemotherapy drug. It works by slowing or stopping cancer cell growth. It is used with other medicines to treat certain types of colon cancer.

In-Depth Information
Select a Medication

ZALTRAP 100mg/4mL Solution for Injection

NDC: 000245840
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Colorectal Cancer

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from light
Discard product if it contains particulate matter, is cloudy, or discolored
Store in original container
Discard unused portion. Do not store for later use.
ZALTRAP 100mg/4mL Solution for Injection

Reported Side Effects for ZALTRAP 100mg/4mL Solution for Injection

Vaginal Fistula Incidence:
<1.5%*
Severity: SEVERE
Onset: DELAYED
Stomach Abnormality Incidence:
<1.5%*
Severity: SEVERE
Onset: DELAYED
Blood Clot Incidence:
<9.0%*
Severity: SEVERE
Onset: DELAYED
Brain Attack Incidence:
<2.6%*
Severity: SEVERE
Onset: EARLY
Chest Pain Incidence:
<1.8%*
Severity: SEVERE
Onset: EARLY
Intestine Abnormality Incidence:
<1.5%*
Severity: SEVERE
Onset: DELAYED
High Blood Pressure Incidence:
0.2%*
Severity: SEVERE
Onset: EARLY
Nose Bleed Incidence:
0.2%*
Severity: SEVERE
Onset: DELAYED
Nephrotic Syndrome Incidence:
0.5%*
Severity: SEVERE
Onset: DELAYED
Brain Deterioration Incidence:
0.5%*
Severity: SEVERE
Onset: DELAYED
Hoarseness Incidence:
0.5%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
0.8%*
Severity: SEVERE
Onset: EARLY
Hole In Intestines Incidence:
0.8%*
Severity: SEVERE
Onset: DELAYED
Stomach Pain Incidence:
1.0-4.0%*
Severity: SEVERE
Onset: EARLY
Headache Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Blood Clot Incidence:
2.6-9.0%*
Severity: SEVERE
Onset: DELAYED
Weight Loss Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Hand And Foot Syndrome Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Bleeding Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Low Platelet Count Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Antibody Formation Incidence:
3.1%*
Severity: MODERATE
Onset: DELAYED
Dehydration Incidence:
4.0%*
Severity: SEVERE
Onset: DELAYED
Weakness Incidence:
5.0%*
Severity: SEVERE
Onset: DELAYED
Blood Clot In Lung Incidence:
5.0%*
Severity: SEVERE
Onset: DELAYED
Runny Nose Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Hemorrhoids Incidence:
6.0%*
Severity: MODERATE
Onset: DELAYED
Protein In The Urine Incidence:
8.0%*
Severity: SEVERE
Onset: DELAYED
Darkened Skin Patches Incidence:
8.0%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
12.0%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
13.0%*
Severity: SEVERE
Onset: EARLY
Mouth Ulcers Incidence:
13.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cell Counts Incidence:
16.0%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
19.0%*
Severity: SEVERE
Onset: EARLY
High Blood Pressure Incidence:
19.0%*
Severity: SEVERE
Onset: EARLY
Low White Blood Cells Incidence:
37.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with ZALTRAP

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5